Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial

Abstract

Controversy still exists on the optimal surgical resection for potentially curable gastric cancer. Much better long-term survival has been reported in retrospective/non-randomized studies with D2 resections that involve a radical extended regional lymphadenectomy than with the standard D1 resections. In this paper we report the long-term survival of patients entered into a randomized study, with follow-up to death or 3 years in 96% of patients and a median follow-up of 6.5 years. In this prospective trial D1 resection (removal of regional perigastric nodes) was compared with D2 resection (extended lymphadenectomy to include level 1 and 2 regional nodes). Central randomization followed a staging laparotomy. Out of 737 patients with histologically proven gastric adenocarcinoma registered, 337 patients were ineligible by staging laparotomy because of advanced disease and 400 were randomized. The 5-year survival rates were 35% for D1 resection and 33% for D2 resection (difference -2%, 95% CI = -12%-8%). There was no difference in the overall 5-year survival between the two arms (HR = 1.10, 95% CI 0.87-1.39, where HR > 1 implies a survival benefit to D1 surgery). Survival based on death from gastric cancer as the event was similar in the D1 and D2 groups (HR = 1.05, 95% CI 0.79-1.39) as was recurrence-free survival (HR = 1.03, 95% CI 0.82-1.29). In a multivariate analysis, clinical stages II and III, old age, male sex and removal of spleen and pancreas were independently associated with poor survival. These findings indicate that the classical Japanese D2 resection offers no survival advantage over D1 surgery. However, the possibility that D2 resection without pancreatico-splenectomy may be better than standard D1 resection cannot be dismissed by the results of this trial.

References 15

1. 1.

   Bonenkamp J. J., Songun I., Hermans J., Sasako M., Welvaart K., Plukker J. T., van Elk P., Obertop H., Gouma D. J., Taat C. W. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745-748.

   Not in our library10.1016/s0140-6736(95)90637-1

2. 2.

   Bunt T. M., Bonenkamp H. J., Hermans J., van de Velde C. J., Arends J. W., Fleuren G., Bruijn J. A. Factors influencing noncompliance and contamination in a randomized trial of "Western" (r1) versus "Japanese" (r2) type surgery in gastric cancer. Cancer. 1994;73(6):1544-1551.

   Not in our library10.1002/1097-0142(19940315)73:6<1544::aid-cncr2820730604>3.0.co;2-4

3. 3.

   Cuschieri A., Fayers P., Fielding J., Craven J., Bancewicz J., Joypaul V., Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995-999.

   Not in our library10.1016/s0140-6736(96)90144-0

4. 4.

   Fass J., Schumpelick V. Principles of radical surgery in gastric carcinoma. Hepatogastroenterology. 1989;36(1):13-17.

   Not in our library

5. 5.

   Griffith J. P., Sue-Ling H. M., Martin I., Dixon M. F., McMahon M. J., Axon A. T., Johnston D. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut. 1995;36(5):684-690.

   Not in our library10.1136/gut.36.5.684

6. 6.

   Jaehne J., Meyer H. J., Maschek H., Geerlings H., Burns E., Pichlmayr R. Lymphadenectomy in gastric carcinoma. A prospective and prognostic study. Arch Surg. 1992;127(3):290-294.

   Not in our library10.1001/archsurg.1992.01420030052010

7. 7.

   Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg. 1981;11(2):127-139.

   Not in our library10.1007/bf02468883

8. 8.

   Maruyama K., Okabayashi K., Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg. 1987;11(4):418-425.

   Not in our library10.1007/bf01655804

9. 9.

   Mine M., Majima S., Harada M., Etani S. End results of gastrectomy for gastric cancer: effect of extensive lymph node dissection. Surgery. 1970;68(5):753-758.

   Not in our library

10. 10.

    Nakajima T., Nishi M. Surgery and adjuvant chemotherapy for gastric cancer. Hepatogastroenterology. 1989;36(2):79-85.

    Not in our library

11. 11.

    Otsuji E., Yamaguchi T., Sawai K., Okamoto K., Takahashi T. End results of simultaneous pancreatectomy, splenectomy and total gastrectomy for patients with gastric carcinoma. Br J Cancer. 1997;75(8):1219-1223.

    Not in our library10.1038/bjc.1997.209

12. 12.

    Siewert J. R., Böttcher K., Roder J. D., Busch R., Hermanek P., Meyer H. J. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993;80(8):1015-1018.

    Not in our library10.1002/bjs.1800800829

13. 13.

    Smith J. W., Shiu M. H., Kelsey L., Brennan M. F. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg. 1991;126(12):1469-1473.

    Not in our library10.1001/archsurg.1991.01410360039007

14. 14.

    Sue-Ling H. M., Johnston D., Martin I. G., Dixon M. F., Lansdown M. R., McMahon M. J., Axon A. T. Gastric cancer: a curable disease in Britain. BMJ. 1993;307(6904):591-596.

    Not in our library10.1136/bmj.307.6904.591

15. 15.

    de Almeida J. C., Bettencourt A., Costa C. S., de Almeida J. M. Curative surgery for gastric cancer: study of 166 consecutive patients. World J Surg. 1994;18(6):889-895.

    Not in our library10.1007/bf00299097

Cited by papers we hold 8

• Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions · 2023
  No notice
• Influential factors on survival in gastric cancer: A single-center study · 2022
  Not checked
• Promoter Methylation of DNA Repair Genes Predicts Disease-free Survival of Gastric Adenocarcinoma after Adjuvant Radiotherapy · 2020
  Not checked
• Evolution of gastric surgery techniques and outcomes · 2016
  Not checked
• Gastric Cancer: Current Status of Diagnosis and Treatment · 2013
  No notice
• Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS) · 2011
  No notice
• A comprehensive overview of radioguided surgery using gamma detection probe technology · 2009
  No notice
• Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer · 2004
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.